Spreading its wings in China with global ambition, EpimAb snags $74M Series B for bispecific work
PHILADELPHIA — A Shanghai-based biotech looking to make it big in the global bispecific boom has $74 million to both deepen and broaden its presence in the clinic.
With the Series B, EpimAb Biotherapeutics hopes to offer not only proof that its platform tech works, but that it works across multiple programs. By the end of next year, it intends to have Phase I/II data on 60 patients for its lead asset targeting EGFR and cMET as well as a second trial — for a dual checkpoint inhibitor — well under way.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.